Ono links up with Reborna Biosciences on RNA targets

Japanese drugmaker Ono Pharmaceutical (TYO: 4528) today revealed that it has entered into a drug discovery collaboration agreement with fellow Japan-based Reborna Biosciences to generate ribonucleic acid (RNA)-targeting novel small molecule in the field of central nervous system.

Under the terms of the agreement, utilizing Reborna’s proprietary RNA-targeting drug discovery platform, the two companies will jointly conduct drug discovery research with the aim of obtaining small molecule compounds that could be drug candidates for the treatment of rare neurological disorders selected by both companies.

Ono will obtain an exclusive option right to develop, manufacture and commercialize the identified small molecule compounds worldwide. Reborna will be eligible to receive an undisclosed upfront payment, research expenses, milestone payments based on research and development progress and sales, as well as tiered royalties based on net sales.